Part 4 of 5 in our EANM'22 Satellite Symposium "Theranostic Innovations" which was held in Barcelona on October 18, 2022.
In this talk, Matthias D'Huyvetter talks about Precirix's Single-Domain Antibodies platform and its oncological applications.
You'll find the other parts here:
Part 1 - Theranostics Roadmap: The Long or the Short Way from Therapeutic to Diagnostic ( • "Theranostic Roadmap" ... )
Part 2 - CXCR4 Based Theranostics for Marginal Zone Lymphoma and Other Hematological Neoplasms (Link on request from marketing.medical@ezag.de)
Part 3 - CXCR4 Based Theranostics for Multiple Myeloma and Leukemia + CXCR4 Q&A (Link on request from marketing.medical@ezag.de)
Part 5 - 68Ga-Trivehexin for PET Imaging of Carcinomas + Single Domain Antibodies / Trivehexin Q&A ( • "68Ga-Trivehexin" by J... )
For more information visit www.medical.ezag.com or contact us at marketing.medical@ezag.de
Негізгі бет "Radiolabeled Single-Domain Antibodies" by Matthias D'Huyvetter - EANM'22 Symposium Part 4 of 5
Пікірлер